Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Pulm Pharmacol Ther. 2016 Jan 5;36:46–52. doi: 10.1016/j.pupt.2015.12.004

Figure 1.

Figure 1

Enrollment

DM: dermatomyositis; PM: polymyositis; IIM: idiopathic inflammatory myopathy; UCTD: undifferentiated connective tissue disease; ILD: interstitial lung disease

Five of seventeen patients (one with dermatomyositis, one with anti-synthetase syndrome, three with UCTD) were excluded from efficacy analysis due to incomplete data. These patients were included in adverse event analysis.